{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:38:48Z","timestamp":1786703928956,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01566-z","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:21:57Z","timestamp":1786702917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relative Dose Intensity and Clinical Outcomes of Using Trifluridine\/Tipiracil with or without Bevacizumab in Patients Aged\u2009\u2265\u200975 Years with Advanced or Recurrent Colorectal Cancer: a Single-Center Retrospective Study"],"prefix":"10.1007","volume":"57","author":[{"given":"Aiko","family":"Tomiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-9841","authenticated-orcid":false,"given":"Michio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiseki","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1634\/theoncologist.2019-0665","volume":"25","author":"H Fujii","year":"2020","unstructured":"Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, et al. Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist. 2020;25:e469\u201376. https:\/\/doi.org\/10.1634\/theoncologist.2019-0665.","journal-title":"Oncologist"},{"key":"1566_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3892\/ol.2025.15387","volume":"31","author":"K Matsumoto","year":"2025","unstructured":"Matsumoto K, Yokoi R, Mizutani C, Asai R, Tajima JY, Endo M, et al. TAS-102 plus bevacizumab as salvage treatment in colorectal cancer: a retrospective study. Oncol Lett. 2025;31:34. https:\/\/doi.org\/10.3892\/ol.2025.15387.","journal-title":"Oncol Lett"},{"key":"1566_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12957-025-04073-w","volume":"23","author":"J Yuan","year":"2025","unstructured":"Yuan J, Lou S, Liu Q, Wei J, Sun X, Sun L, et al. TAS-102 plus bevacizumab versus TAS-102 alone for metastatic colorectal cancer: a systematic review and meta-analysis. World J Surg Oncol. 2025;23:420. https:\/\/doi.org\/10.1186\/s12957-025-04073-w.","journal-title":"World J Surg Oncol"},{"key":"1566_CR4","first-page":"18","volume":"1","author":"L Repetto","year":"2003","unstructured":"Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1:18\u201324.","journal-title":"J Support Oncol"},{"key":"1566_CR5","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1093\/oncolo\/oyad296","volume":"29","author":"Y Kito","year":"2024","unstructured":"Kito Y, Kawakami H, Mitani S, Nishina S, Matsumoto T, Tsuzuki T, et al. Trifluridine\/tipiracil plus bevacizumab for vulnerable patients with pretreated metastatic colorectal cancer: a retrospective study (WJOG14520G). Oncologist. 2024;29:e330\u20136. https:\/\/doi.org\/10.1093\/oncolo\/oyad296.","journal-title":"Oncologist"},{"key":"1566_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2214963.","journal-title":"N Engl J Med"},{"key":"1566_CR7","unstructured":"US Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"1566_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"1566_CR9","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1414325.","journal-title":"N Engl J Med"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26:e1609\u201318. https:\/\/doi.org\/10.1002\/onco.13822.","journal-title":"Oncologist"},{"key":"1566_CR11","first-page":"54","volume":"47","author":"Y Okuda","year":"2021","unstructured":"Okuda Y, Shinada M, Mikame Y, Saitoh T, Kezuka C, Hoshi C, et al. Relative dose intensity and therapeutic effects of TAS-102 for colorectal cancer. Iryo Yakugaku. 2021;47:54\u20139.","journal-title":"Iryo Yakugaku"},{"key":"1566_CR12","doi-asserted-by":"publisher","first-page":"115470","DOI":"10.1016\/j.ejca.2025.115470","volume":"222","author":"R Moretto","year":"2025","unstructured":"Moretto R, Rossini D, Polito MG, Antoniotti C, Intini R, Conca V, et al. The relative dose intensity of first-line FOLFOXIRI and FOLFOX\/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: a pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer. 2025;222:115470. https:\/\/doi.org\/10.1016\/j.ejca.2025.115470.","journal-title":"Eur J Cancer"},{"key":"1566_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/mco.2025.2915","volume":"24","author":"C Suzuki","year":"2025","unstructured":"Suzuki C, Kimura M, Go M, Ikeda Y, Usami E. Impact of TAS-102 dose reduction on severe neutropenia and survival outcomes in patients with metastatic colorectal cancer and prior chemotherapy-induced neutropenia. Mol Clin Oncol. 2025;24:6. https:\/\/doi.org\/10.3892\/mco.2025.2915.","journal-title":"Mol Clin Oncol"},{"key":"1566_CR14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30634-9","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 2017;18:1172\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(17)30634-9.","journal-title":"Lancet Oncol"},{"key":"1566_CR15","doi-asserted-by":"publisher","first-page":"101614","DOI":"10.1016\/j.esmoop.2023.101614","volume":"8","author":"Y Kagawa","year":"2023","unstructured":"Kagawa Y, Shinozaki E, Okude R, Tone T, Kunitomi Y, Nakashima M. Real-world evidence of trifluridine\/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ESMO Open. 2023;8:101614. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101614","journal-title":"ESMO Open"},{"key":"1566_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12885-023-11618-3","volume":"23","author":"D Watanabe","year":"2023","unstructured":"Watanabe D, Fujii H, Ohata K, Iihara H, Makiyama A, Kobayashi R, et al. Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. BMC Cancer. 2023;23:1078. https:\/\/doi.org\/10.1186\/s12885-023-11618-3.","journal-title":"BMC Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01566-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:22:01Z","timestamp":1786702921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01566-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01566-z","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"189"}}